- The gastrointestinal (GI) tolerability of ASC47 in combination with semaglutide was significantly better than placebo in combination with semaglutide (semaglutide monotherapy). The incidence of vomiting was 6.7% in ASC47 in combination with semaglutide group compared to 57.1% in the semaglutide monotherapy group. - Ultra-long-acting subcutaneous (SQ) depot formulation of ASC47...
BEIJING, June 1, 2025 /PRNewswire/ -- China Liberal Education Holdings Limited ("China Liberal" or the "Company") (Nasdaq: CLEU), a China-based company that provides technological...
SHANGHAI, June 1, 2025 /PRNewswire/ -- On May 30, 2025, the most influential pop culture exhibition in Latin America, CCXP Mexico 2025, grandly opened...